2PU Stock Overview
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Pulmatrix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.94 |
| 52 Week High | US$2.70 |
| 52 Week Low | US$1.41 |
| Beta | 0.95 |
| 1 Month Change | 31.97% |
| 3 Month Change | 17.86% |
| 1 Year Change | -23.77% |
| 3 Year Change | -87.80% |
| 5 Year Change | -89.54% |
| Change since IPO | -99.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2PU | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 14.1% | -2.9% | -2.5% |
| 1Y | -23.8% | -31.3% | -0.4% |
Return vs Industry: 2PU exceeded the German Pharmaceuticals industry which returned -29.6% over the past year.
Return vs Market: 2PU underperformed the German Market which returned 1% over the past year.
Price Volatility
| 2PU volatility | |
|---|---|
| 2PU Average Weekly Movement | 8.7% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2PU's share price has been volatile over the past 3 months.
Volatility Over Time: 2PU's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 22 | Ted Raad | www.pulmatrix.com |
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine.
Pulmatrix, Inc. Fundamentals Summary
| 2PU fundamental statistics | |
|---|---|
| Market cap | €7.26m |
| Earnings (TTM) | -€13.23m |
| Revenue (TTM) | €6.84m |
1.0x
P/S Ratio-0.5x
P/E RatioIs 2PU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2PU income statement (TTM) | |
|---|---|
| Revenue | US$7.30m |
| Cost of Revenue | US$15.52m |
| Gross Profit | -US$8.22m |
| Other Expenses | US$5.90m |
| Earnings | -US$14.12m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.87 |
| Gross Margin | -112.63% |
| Net Profit Margin | -193.49% |
| Debt/Equity Ratio | 0% |
How did 2PU perform over the long term?
See historical performance and comparison